Efficacy
NSCLC, tumor, death, SD, PD
NON-SMALL CELL LUNG CANCER, DISEASE, NSCLC, TUMOR
No patients in the phase Ib portion of the study achieved CR or PR, though stable disease (SD) was observed in seven patients across the four dosing schedules. In the phase II NSCLC portion of the trial, 6 (24%) patients had PR, no patient achieved CR, 4 (16%) had stable disease (SD), 9 (36%) patients had progressive disease (PD), 1 of 9 progressed patients had confirmed PR after initial pseudo-progression (delayed responder), and 6 (24%) patients were deemed not evaluable (NE) due to treatment discontinuation (Fig. Waterfall plot of best overall response rate (ORR) according to RECIST in the in NSCLC Cohort. Information is provided about baseline PD-L1 expression in 18 patients (number in blue), and tumor mutation burden (TMB) in 7 patients (number in red). Abbreviations: NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1Efficacy outcomes in the phase II NSCLC cohort. Kaplan–Meier plots of Progression-Free Survival (